|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
US4364934A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
JP3019994B2
(ja)
|
1987-11-30 |
2000-03-15 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
|
|
WO1989007970A1
(en)
|
1988-03-02 |
1989-09-08 |
Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
EP0406309A4
(en)
|
1988-03-25 |
1992-08-19 |
The University Of Virginia Alumni Patents Foundation |
Oligonucleotide n-alkylphosphoramidates
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
WO1991018913A1
(en)
|
1990-06-07 |
1991-12-12 |
City Of Hope |
Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
|
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5789157A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5650275A
(en)
|
1990-06-11 |
1997-07-22 |
Nexstar Pharmacueticals Inc |
Target detection method using spectroscopically detectable nucleic acid ligands
|
|
US5864026A
(en)
|
1990-06-11 |
1999-01-26 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
ATE318832T1
(de)
|
1990-06-11 |
2006-03-15 |
Gilead Sciences Inc |
Verfahren zur vervendung von nukleinsäureliganden
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
US6365730B1
(en)
|
1990-06-19 |
2002-04-02 |
Gene Shears Pty. Limited |
DNA-Armed ribozymes and minizymes
|
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
|
AU651380B2
(en)
|
1990-07-16 |
1994-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Selection of ribozymes that efficiently cleave target RNA
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
AU649074B2
(en)
|
1990-10-12 |
1994-05-12 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Modified ribozymes
|
|
EP0563251A1
(en)
|
1990-12-20 |
1993-10-06 |
Exxon Chemical Patents Inc. |
Uv/eb curable butyl copolymers for lithographic and corrosion-resistant coating applications
|
|
DE69233697T2
(de)
|
1991-03-01 |
2008-01-24 |
Dyax Corp., Cambridge |
Verfahren zur Entwicklung von bindenden Mikroproteinen
|
|
PT100379B
(pt)
|
1991-04-10 |
1999-01-29 |
Scripps Research Inst |
Bibliotecas de receptores heterodimericos usando fagomideos
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US6100099A
(en)
|
1994-09-06 |
2000-08-08 |
Abbott Laboratories |
Test strip having a diagonal array of capture spots
|
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5436143A
(en)
|
1992-12-23 |
1995-07-25 |
Hyman; Edward D. |
Method for enzymatic synthesis of oligonucleotides
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
DK0733059T3
(da)
|
1993-12-09 |
2000-10-16 |
Univ Jefferson |
Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5650502A
(en)
|
1994-11-09 |
1997-07-22 |
Hybridon, Inc. |
Ribozyme analogs having rigid non-nucleotidic linkers
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5693773A
(en)
|
1995-06-07 |
1997-12-02 |
Hybridon Incorporated |
Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5989823A
(en)
|
1998-09-18 |
1999-11-23 |
Nexstar Pharmaceuticals, Inc. |
Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
BRPI0008131B8
(pt)
|
1999-02-12 |
2021-05-25 |
Daiichi Sankyo Co Ltd |
composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
|
|
US6136603A
(en)
|
1999-03-26 |
2000-10-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of interleukin-5 signal transduction
|
|
US6569630B1
(en)
|
1999-07-02 |
2003-05-27 |
Conceptual Mindworks, Inc. |
Methods and compositions for aptamers against anthrax
|
|
EP1264826B1
(en)
|
2000-02-22 |
2005-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Novel imidazoline compounds
|
|
AU5752601A
(en)
|
2000-05-04 |
2001-11-12 |
Avi Biopharma Inc |
Splice-region antisense composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US7575886B2
(en)
|
2002-03-11 |
2009-08-18 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
|
US20040121353A1
(en)
|
2002-05-23 |
2004-06-24 |
Ceptyr, Inc. |
Modulation of TCPTP signal transduction by RNA interference
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
EP2284269B1
(en)
|
2002-11-18 |
2017-08-09 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
EP2530155B1
(en)
|
2002-11-25 |
2016-03-16 |
Masafumi Matsuo |
ENA nucleic acid drugs modifying splicing in mRNA precursor
|
|
WO2004058717A1
(en)
|
2002-12-20 |
2004-07-15 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
CA2515623A1
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of survivin expression
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
US7592143B2
(en)
|
2003-04-18 |
2009-09-22 |
Cytovia, Inc. |
Methods of treating diseases responsive to induction of apoptosis and screening assays
|
|
MXPA06000619A
(es)
|
2003-07-15 |
2006-04-11 |
Hybridon Inc |
Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
|
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
GB0324854D0
(en)
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
|
DE602005020745D1
(de)
|
2004-02-10 |
2010-06-02 |
Zystor Therapeutics Inc |
Saure alpha-glukosidase und fragmente davon
|
|
WO2005087217A1
(en)
|
2004-03-05 |
2005-09-22 |
The General Hospital Corporation |
Compositions and methods for modulating interaction between polypeptides
|
|
WO2005113571A2
(en)
|
2004-05-13 |
2005-12-01 |
The University Of North Carolina At Chapel Hill |
Methods for the delivery of oligomeric compounds
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
ES2627917T3
(es)
|
2004-06-28 |
2017-08-01 |
The University Of Western Australia |
Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US7807619B2
(en)
|
2004-11-01 |
2010-10-05 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
US7807648B2
(en)
|
2005-10-06 |
2010-10-05 |
University Of Delaware |
G-rich polynucleotides for the treatment of Huntington's Disease
|
|
JP2007104971A
(ja)
|
2005-10-14 |
2007-04-26 |
New Industry Research Organization |
ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
DE602007009487D1
(de)
|
2006-01-27 |
2010-11-11 |
Isis Pharmaceutical Inc |
6-modifizierte bicyclische nukleinsäureanaloga
|
|
WO2007089612A2
(en)
|
2006-01-30 |
2007-08-09 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing bacterial infections
|
|
CN101404927A
(zh)
|
2006-02-09 |
2009-04-08 |
建新公司 |
慢速脑室内递送
|
|
US20070249014A1
(en)
|
2006-02-10 |
2007-10-25 |
Invitrogen Corporation |
Labeling and detection of post translationally modified proteins
|
|
CA3042781C
(en)
|
2006-04-03 |
2021-10-19 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
EP2505646A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of CRP
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
EP2076597A2
(en)
|
2006-10-09 |
2009-07-08 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of pcsk9
|
|
EP2410053B2
(en)
|
2006-10-18 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
|
WO2008067480A2
(en)
|
2006-11-29 |
2008-06-05 |
Nationwide Children's Hospital |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
|
CN102978185B
(zh)
|
2007-01-18 |
2015-02-11 |
建新公司 |
包含氨基氧基基团的寡糖及其轭合物
|
|
US8318438B2
(en)
|
2007-03-01 |
2012-11-27 |
The United States Of America As Represented By The Secretary Of The Air Force |
Aptamer-based assays
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US9050333B2
(en)
|
2008-07-08 |
2015-06-09 |
Duke University |
Method of treating glycogen storage disease type III with human acid α-glucosidase
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
SI2607484T1
(sl)
|
2008-10-27 |
2016-11-30 |
Biomarin Technologies B.V. |
Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
|
|
EP3608330B1
(en)
|
2008-12-16 |
2022-11-09 |
Genzyme Corporation |
Synthetic intermediates for preparing oligosaccharide-protein conjugates
|
|
WO2010096369A1
(en)
|
2009-02-18 |
2010-08-26 |
Amicus Therapeutics, Inc. |
Mouse model for pompe disease and methods of use thereof
|
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
|
EP2427554B1
(en)
*
|
2009-05-08 |
2016-11-16 |
CuRNA, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
|
HUE040445T2
(hu)
|
2009-11-12 |
2019-03-28 |
Univ Western Australia |
Antiszensz molekulák és eljárások betegségek kezelésére
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US8859629B2
(en)
|
2010-04-27 |
2014-10-14 |
Synaffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
KR101981705B1
(ko)
|
2010-05-28 |
2019-05-24 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
SG186451A1
(en)
|
2010-07-12 |
2013-01-30 |
Covx Technologies Ireland Ltd |
Multifunctional antibody conjugates
|
|
ES2756326T3
(es)
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
EP2606152B2
(en)
|
2010-08-18 |
2025-03-12 |
Fred Hutchinson Cancer Center |
Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
EP3118316A1
(en)
|
2010-09-02 |
2017-01-18 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
BR112013020273A2
(pt)
|
2011-02-08 |
2016-10-18 |
Charlotte Mecklenburg Hospital |
oligonucleotídeos antissenso
|
|
AU2012246822B2
(en)
|
2011-04-22 |
2017-05-25 |
Biomarin Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
|
|
WO2012178173A1
(en)
|
2011-06-24 |
2012-12-27 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
CA2842798C
(en)
|
2011-07-25 |
2021-02-23 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
WO2013019623A2
(en)
|
2011-07-29 |
2013-02-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
|
|
US20130066063A1
(en)
|
2011-09-09 |
2013-03-14 |
John Cooke Hodges |
Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
|
|
HK1200484A1
(zh)
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
EP2788026A4
(en)
|
2011-12-05 |
2015-08-05 |
Univ Duke |
V1V2 IMMUNOGENIC
|
|
CA2858576A1
(en)
|
2011-12-06 |
2013-06-13 |
Research Institute At Nationwide Children's Hospital |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
CN108588073A
(zh)
|
2011-12-28 |
2018-09-28 |
日本新药株式会社 |
反义核酸
|
|
TW201333040A
(zh)
|
2012-01-06 |
2013-08-16 |
Bioalliance Cv |
抗－輸鐵蛋白受器之抗體及其使用方法
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013120038A2
(en)
|
2012-02-10 |
2013-08-15 |
Regents Of The University Of Minnesota |
Morpholino targeting dux4 for treating fshd
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
CA2867237C
(en)
|
2012-03-15 |
2024-01-02 |
Wouter Vervecken |
Methods and materials for treatment of pompe's disease
|
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
|
PT2841578T
(pt)
|
2012-04-23 |
2017-08-10 |
Biomarin Tech Bv |
Resumo
|
|
CN104603271B
(zh)
|
2012-07-03 |
2019-07-19 |
马林生物科技有限公司 |
用于治疗肌肉萎缩症患者的寡核苷酸
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
EP4678239A3
(en)
|
2012-08-01 |
2026-04-08 |
Ikaika Therapeutics, Inc. |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
US10111962B2
(en)
|
2012-09-25 |
2018-10-30 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
HRP20180268T4
(hr)
|
2012-10-23 |
2026-03-27 |
Synaffix B.V. |
Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
US9217148B2
(en)
|
2013-03-14 |
2015-12-22 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
HK1220154A1
(zh)
|
2013-03-15 |
2017-04-28 |
Sarepta Therapeutics, Inc. |
改进的用於治疗肌营养不良的组合物
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
WO2015023939A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
CA2921457A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Heterochromatin forming non-coding rnas
|
|
CA2922544A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Engineered anti-dll3 conjugates and methods of use
|
|
AU2014321211A1
(en)
|
2013-09-23 |
2016-05-05 |
President And Fellows Of Harvard College |
Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy
|
|
WO2015057064A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057065A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
JP6616189B2
(ja)
|
2013-12-25 |
2019-12-04 |
Ｊｃｒファーマ株式会社 |
血液脳関門を通過する新規抗トランスフェリン受容体抗体
|
|
EP3094728B1
(en)
|
2014-01-16 |
2022-03-09 |
Wave Life Sciences Ltd. |
Chiral design
|
|
CN106660967A
(zh)
|
2014-01-24 |
2017-05-10 |
西纳福克斯股份有限公司 |
(杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
|
|
EP3097080A1
(en)
|
2014-01-24 |
2016-11-30 |
SynAffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
JP2017513921A
(ja)
|
2014-03-03 |
2017-06-01 |
アーチャルジー、スジャータ |
ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
|
|
BR112016020618B1
(pt)
|
2014-03-12 |
2023-04-04 |
Nippon Shinyaku Co., Ltd. |
Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
|
|
EP3119909B1
(en)
|
2014-03-18 |
2019-11-13 |
Fred Hutchinson Cancer Research Center |
Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd)
|
|
WO2015163476A1
(ja)
|
2014-04-25 |
2015-10-29 |
ヤマハモーターパワープロダクツ株式会社 |
エンジン
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
AR100560A1
(es)
|
2014-05-23 |
2016-10-12 |
Genzyme Corp |
Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
|
|
PT3159409T
(pt)
|
2014-06-17 |
2020-01-21 |
Nippon Shinyaku Co Ltd |
Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
|
|
WO2016022536A2
(en)
|
2014-08-04 |
2016-02-11 |
MiRagen Therapeutics, Inc. |
Inhibitors of myh7b and uses thereof
|
|
EP3177633B1
(en)
|
2014-08-04 |
2022-07-20 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
WO2016025519A1
(en)
|
2014-08-11 |
2016-02-18 |
Shire Human Genetic Therapies, Inc. |
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
JP6851964B2
(ja)
|
2014-09-30 |
2021-03-31 |
アミカス セラピューティックス インコーポレイテッド |
炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
|
|
EP3733209A1
(en)
|
2014-10-03 |
2020-11-04 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
AU2015349890B2
(en)
|
2014-11-21 |
2018-08-30 |
Merck Sharp & Dohme Llc |
Insulin receptor partial agonists
|
|
US20190002876A1
(en)
|
2014-12-09 |
2019-01-03 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treatment of friedreich's ataxia
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
MX2017011004A
(es)
|
2015-02-27 |
2018-02-09 |
Sarepta Therapeutics Inc |
Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
KR102644053B1
(ko)
|
2015-05-19 |
2024-03-06 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
펩티드 올리고뉴클레오티드 콘주게이트
|
|
CA2990785C
(en)
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
IL257065B
(en)
|
2015-07-22 |
2022-07-01 |
Inatherys |
Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases
|
|
HUE050061T2
(hu)
|
2015-09-15 |
2020-12-28 |
Nippon Shinyaku Co Ltd |
Antiszensz nukleinsav
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
EP3353301A1
(en)
|
2015-09-21 |
2018-08-01 |
Association Institut de Myologie |
Antisense oligonucleotides and uses thereof
|
|
EP3332008A4
(en)
|
2015-09-23 |
2019-01-16 |
Université Laval |
CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF
|
|
MA46427A
(fr)
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス， インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
SG10201912763QA
(en)
|
2015-11-05 |
2020-02-27 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
EP4032902A1
(en)
|
2015-12-18 |
2022-07-27 |
Eisai R&D Management Co., Ltd. |
C-terminal lysine conjugated immunoglobulins
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
WO2017143156A1
(en)
|
2016-02-19 |
2017-08-24 |
Genisphere Llc |
Nucleic acid carriers and therapeutic methods of use
|
|
KR102618519B1
(ko)
|
2016-03-30 |
2023-12-28 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
재조합 산 알파-글루코시다제를 포함하는 제형
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
BR112018070249A2
(pt)
|
2016-04-02 |
2019-01-29 |
Research Institute At Nationwide Children's Hospital |
sistema promotor de u6 modificada para expressão específica de tecido
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
JP2019516679A
(ja)
|
2016-05-04 |
2019-06-20 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
生物活性剤に関する方法および組成物
|
|
WO2017205191A1
(en)
|
2016-05-24 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
DK3473270T5
(da)
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
AU2017291960B2
(en)
|
2016-07-05 |
2024-03-14 |
Biomarin Technologies B.V. |
Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
US20190330626A1
(en)
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
KR102617502B1
(ko)
|
2016-09-12 |
2023-12-26 |
제네똥 |
산-알파 글루코시다제 변이체 및 이의 용도
|
|
EP3516062A1
(en)
|
2016-09-21 |
2019-07-31 |
Alnylam Pharmaceuticals, Inc. |
Myostatin irna compositions and methods of use thereof
|
|
BR112019009953A2
(pt)
|
2016-11-16 |
2019-10-08 |
Academisch Ziekenhuis Leiden |
substâncias direcionadas a vários órgãos ou tecidos selecionados
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
AU2017364106A1
(en)
|
2016-11-28 |
2019-06-20 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing
|
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
PT4122497T
(pt)
|
2016-12-19 |
2024-06-12 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
|
TWI833178B
(zh)
|
2016-12-26 |
2024-02-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
MX2019007824A
(es)
|
2016-12-28 |
2019-09-09 |
Japan Chem Res |
Preparacion liofilizada.
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
KR20240172236A
(ko)
|
2017-01-06 |
2024-12-09 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
CA3049791A1
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
AU2018281280B2
(en)
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EP3684378A4
(en)
|
2017-09-19 |
2021-06-16 |
Children's National Medical Center |
GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
SG11202002517RA
(en)
|
2017-09-22 |
2020-04-29 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
MA49923A
(fr)
|
2017-10-02 |
2020-06-24 |
Res Inst Nationwide Childrens Hospital |
Système de déciblage de miarn pour interférence spécifique d'un tissu
|
|
SG11202003126VA
(en)
|
2017-10-04 |
2020-05-28 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
MA50579A
(fr)
|
2017-11-09 |
2020-09-16 |
Crispr Therapeutics Ag |
Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
EP3720504A1
(en)
|
2017-12-06 |
2020-10-14 |
Synaffix B.V. |
Enediyne conjugates
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
EP3735252A4
(en)
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
EP3746557A1
(en)
|
2018-01-31 |
2020-12-09 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for correcting dystrophin mutations in human cardiomyocytes
|
|
US12458668B2
(en)
|
2018-02-02 |
2025-11-04 |
Fred Hutchinson Cancer Center |
Methods for treating facioscapulohumeral muscular dystrophy
|
|
CN111683972A
(zh)
|
2018-02-05 |
2020-09-18 |
Jcr制药股份有限公司 |
用于将药剂递送至肌肉的方法
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
JP2021521140A
(ja)
|
2018-04-12 |
2021-08-26 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
WO2019209764A2
(en)
|
2018-04-26 |
2019-10-31 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers and oligomer conjugates for muscular dystrophy
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
AU2019266550A1
(en)
|
2018-05-11 |
2020-11-26 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20220251551A1
(en)
|
2018-06-13 |
2022-08-11 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
|
WO2019246480A1
(en)
|
2018-06-21 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
CN112930193A
(zh)
|
2018-08-02 |
2021-06-08 |
达因疗法公司 |
肌肉靶向复合物及其在治疗肌肉萎缩中的用途
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3830127A4
(en)
|
2018-08-02 |
2022-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CA3108386A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
CN112955154A
(zh)
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3108328A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
|
|
AU2019315593B2
(en)
|
2018-08-02 |
2026-05-21 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
US11708569B2
(en)
|
2018-08-29 |
2023-07-25 |
University Of Copenhagen |
Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
EP3876998A1
(en)
|
2018-11-05 |
2021-09-15 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
AU2019392928A1
(en)
|
2018-12-06 |
2021-06-17 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
JP2022516515A
(ja)
|
2018-12-31 |
2022-02-28 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止
|
|
EP3946376A1
(en)
|
2019-03-28 |
2022-02-09 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
WO2020247782A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
JP7581252B2
(ja)
|
2019-06-06 |
2024-11-12 |
アビディティー バイオサイエンシーズ，インク． |
Ｕｎａアミダイトおよびその使用
|
|
CN114025805B
(zh)
|
2019-06-07 |
2025-01-24 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
EP3987029A1
(en)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
EP3997228A4
(en)
|
2019-07-09 |
2024-05-15 |
The Governors of the University of Alberta |
SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP2023503644A
(ja)
|
2019-11-27 |
2023-01-31 |
ディー・ティー・エックス・ファーマ・インコーポレイテッド |
デュシェンヌ型筋ジストロフィーの治療のための化合物および方法
|
|
MX2022007399A
(es)
|
2019-12-20 |
2022-09-19 |
Codexis Inc |
Variantes de alfa-glucosidasa ácida diseñadas.
|
|
US20230111212A1
(en)
|
2020-01-10 |
2023-04-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
CN122124274A
(zh)
|
2020-01-10 |
2026-06-02 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
JP7858532B2
(ja)
|
2020-01-10 |
2026-05-14 |
ダイン セラピューティクス，インコーポレーテッド |
筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
EP4087653A4
(en)
|
2020-01-10 |
2024-06-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN115427448A
(zh)
|
2020-01-10 |
2022-12-02 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
US20230117883A1
(en)
|
2020-01-24 |
2023-04-20 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
IL295022A
(en)
|
2020-01-31 |
2022-09-01 |
Dyne Therapeutics Inc |
Antibody against transferrin receptor and uses thereof
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
KR102927945B1
(ko)
|
2020-03-27 |
2026-02-23 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
|
US20230330246A1
(en)
|
2020-05-05 |
2023-10-19 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
US20230256112A1
(en)
|
2020-07-23 |
2023-08-17 |
Dyne Therapeutics, lnc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
MX2023000958A
(es)
|
2020-07-23 |
2023-04-14 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica.
|
|
CN116348139A
(zh)
|
2020-07-23 |
2023-06-27 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
MX2023000984A
(es)
|
2020-07-23 |
2023-05-03 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
EP4185320A4
(en)
|
2020-07-23 |
2025-10-08 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
|
|
AU2021313058A1
(en)
|
2020-07-23 |
2023-03-30 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
AR123420A1
(es)
|
2020-09-01 |
2022-11-30 |
Ultragenyx Pharmaceutical Inc |
Inhibidores de dux4 y métodos de uso de estos
|
|
KR20230079068A
(ko)
|
2020-09-03 |
2023-06-05 |
다인 세라퓨틱스, 인크. |
단백질-올리고뉴클레오티드 복합체의 제조 방법
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
CA3203585A1
(en)
|
2020-11-30 |
2022-06-02 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
|
KR20230117182A
(ko)
|
2020-12-04 |
2023-08-07 |
다인 세라퓨틱스, 인크. |
항체-올리고뉴클레오티드 복합체 및 그의 용도
|
|
EP4271478A4
(en)
|
2020-12-31 |
2025-03-26 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR TREATING FACIOSCAPULOHUMERAL MYOPATHY
|
|
AU2021414227A1
(en)
|
2020-12-31 |
2023-07-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20240336915A1
(en)
|
2021-01-22 |
2024-10-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dux4 expression
|
|
KR20240009393A
(ko)
|
2021-03-31 |
2024-01-22 |
엔트라다 테라퓨틱스, 인크. |
사이클릭 세포 침투 펩티드
|
|
EP4314298A4
(en)
|
2021-04-02 |
2026-06-03 |
Avidity Biosciences Inc |
ANTIBODY-OLIGONUCLEOTIDE CONJUGATES AND ANTIBODY-PEPTIDE-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND EXON-SKIPPING INDUCTION METHODS
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
WO2022232478A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
EP4359534A4
(en)
|
2021-06-21 |
2026-07-22 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES IN THE TREATMENT OF POMPE DISEASE
|
|
CA3222816A1
(en)
|
2021-06-21 |
2022-12-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
JPWO2022270585A1
(enExample)
|
2021-06-23 |
2022-12-29 |
|
|
|
JP2024525613A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
US20240318176A1
(en)
|
2021-07-09 |
2024-09-26 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3226298A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283623A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
CN118591391A
(zh)
|
2021-07-09 |
2024-09-03 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
CN118401553A
(zh)
|
2021-07-09 |
2024-07-26 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
EP4366774A4
(en)
|
2021-07-09 |
2025-11-19 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
|
|
EP4389891A4
(en)
|
2021-08-19 |
2025-10-29 |
Univ Nat Corp Tokyo Medical & Dental |
MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
|
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
|
|
EP4395831A1
(en)
|
2021-09-01 |
2024-07-10 |
Entrada Therapeutics, Inc. |
Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
|
|
IL311507A
(en)
|
2021-09-16 |
2024-05-01 |
Dyne Therapeutics Inc |
Dosing of muscle targeting complexes for the treatment of dystrophinopathy
|
|
EP4401792A4
(en)
|
2021-09-16 |
2025-12-03 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
EP4426356A1
(en)
|
2021-11-01 |
2024-09-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating dystrophinopathies
|
|
JP2024546436A
(ja)
|
2021-11-12 |
2024-12-24 |
ダイン セラピューティクス，インコーポレーテッド |
顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
US20250082759A1
(en)
|
2021-12-22 |
2025-03-13 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
EP4452281A1
(en)
|
2021-12-22 |
2024-10-30 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
|
|
CA3240612A1
(en)
|
2021-12-22 |
2023-06-29 |
Miriam Verena Bujny |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
EP4469576A4
(en)
|
2022-01-27 |
2026-04-15 |
Univ Alberta |
Antisense therapeutic products conjugate to pre-MIARN splicing modulating peptides for the treatment of diseases
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
EP4493693A1
(en)
|
2022-03-17 |
2025-01-22 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
US20250249117A1
(en)
|
2022-04-15 |
2025-08-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating myotonic dystrophy
|
|
WO2023201324A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
WO2024011135A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
AU2023303022A1
(en)
|
2022-07-06 |
2025-01-02 |
Dyne Therapeutics, Inc. |
Cns targeting complexes and uses thereof
|
|
EP4590311A2
(en)
|
2022-09-21 |
2025-07-30 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
|
JP2026503873A
(ja)
|
2022-10-31 |
2026-02-02 |
ダイン セラピューティクス，インコーポレーテッド |
Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用
|
|
IL321025A
(en)
|
2022-11-21 |
2025-07-01 |
Pepgen Inc |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024149282A1
(en)
|
2023-01-10 |
2024-07-18 |
Ausperbio Therapeutics Inc. |
Modified multi-segmented antisense oligonucleotides for use
|
|
AU2024230817A1
(en)
|
2023-02-27 |
2025-09-11 |
Dyne Therapeutics, Inc. |
Methods and compositions for inhibiting progression of intramuscular fibrosis
|